Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.45 |
| ▸ | HTR3A | P46098 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025467 | 0.88 | TLR8 (0.48) | TLR7 | |
| SCHEMBL30886384 | 0.88 | TLR8 (0.48) | TLR7 | |
| SCHEMBL23102167 | 0.87 | TLR8 (0.47) | TLR7 | |
| SCHEMBL3498559 | 0.86 | NPC1 (0.45) | HRH3NPC1TSHRRAB9AACHE | |
| SCHEMBL3499273 | 0.84 | TLR7 (0.50) | HRH3TLR7 | |
| SCHEMBL3503268 | 0.84 | ACSS2 (0.47) | TSHRSLC6A4 | |
| SCHEMBL10025563 | 0.81 | NPC1 (0.42) | HRH3NPC1TSHRRAB9ATLR9 | |
| SCHEMBL3498283 | 0.80 | TLR8 (0.49) | — | |
| SCHEMBL3498232 | 0.80 | NPC1 (0.42) | HRH3NPC1TSHRRAB9ATLR9 | |
| SCHEMBL3631276 | 0.77 | DRD2 (0.42) | HRH3NPC1TSHRRAB9AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642265-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20050165007-A1 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165007-A1 | Benzimidazoles and analogs thereof as antivirals | ZC3HAV1, NXF1, ZC3HAV1L | HRH3 1057/4885NPC1 666/4885TSHR 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.